1. Median progression-free survival was greater in the SBRT group than in the standard-of-care group. 2. Patients with NSCLC displayed a significant survival benefit with SBRT in comparison to patients with breast cancer. Evidence Rating Level: 1 (Excellent) Study Rundown: Most patients with metastatic breast cancer develop resistance to systemic therapy. Stereotactic body radiotherapy (SBRT)
A Type II extension of indication application seeking the approval of amivantamab in combination with carboplatin and pemetrexed for the frontline treatment of adult patients with advanced non–small cell lung cancer and activating EGFR exon 20 insertion mutations has been submitted to the European Medicines Agency.
1. 4-year event-free survival was significantly greater in I-SABR (77%) versus SABR alone (53%). 2. More patients in the I-SABR group experienced grade 3 immunological adverse events. Evidence Rating Level: 1 (Excellent) Study Rundown: Standard treatment for early-stage inoperable non-small-cell lung cancer (NSCLC) includes stereotactic ablative radiotherapy (SABR). However, relapses remain common. Although immunotherapy may has
1. 4-year event-free survival was significantly greater in I-SABR (77%) versus SABR alone (53%). 2. More patients in the I-SABR group experienced grade 3 immunological adverse events. Evidence Rating Level: 1 (Excellent) Study Rundown: Standard treatment for early-stage inoperable non-small-cell lung cancer (NSCLC) includes stereotactic ablative radiotherapy (SABR). However, relapses remain common. Although immunotherapy may